NCT02427243View on ClinicalTrials.gov

A Study in Healthy Volunteers to Assess the Relative Bioavailability and Tolerability of Two Crenezumab Formulations Following Administration of a Single Subcutaneous Dose

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Healthy Volunteer
Interventions
DRUG

Crenezumab

DRUG

Crenezumab

Trial Locations (2)

47710

Evansville

75247

Dallas

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT02427243 - A Study in Healthy Volunteers to Assess the Relative Bioavailability and Tolerability of Two Crenezumab Formulations Following Administration of a Single Subcutaneous Dose | Biotech Hunter | Biotech Hunter